Patients with PKU are susceptible to neurocognitive and psychiatric issues even if following dietary restrictions. Assessment of patients is the first step in management, which may include strategies to improve functioning and control blood phenylalanine levels, as well as addressing any comorbid conditions. Healthcare professionals should recognize potential issues, empower patients, and refer to psychologists or psychiatrists for ongoing monitoring and intervention.
Autism challenges the individual, their family, the community and the practitioner. The complexity and variety of symptoms that define Autism Spectrum Disorders (ASD) require service providers to constantly update their knowledge and skills to best serve these individuals. Sensorimotor synchronization training with Interactive Metronome (IM), as part of a comprehensive treatment plan, has the potential to directly and positively influence the person’s ability to learn and engage with the world around him. This course will introduce practitioners to new advances in our understanding of ASD, including the pivotal role of timing & rhythm for speech, language, pragmatic, cognitive, motor and sensory processing skills. Participants will learn strategies to evaluate the unique strengths and needs of each individual with ASD as well as how to develop and implement effective IM training with consideration for communication, sensory, motor & behavioral challenges. The expert presenter will incorporate several videos and real examples to illustrate techniques. Take the course at https://secure.interactivemetronome.com/NetSite/IM/CEU/SimpleRegistration.aspx?course_id=2778
Autism challenges the individual, their family, the community and the practitioner. The complexity and variety of symptoms that define Autism Spectrum Disorders (ASD) require service providers to constantly update their knowledge and skills to best serve these individuals. Sensorimotor synchronization training with Interactive Metronome (IM), as part of a comprehensive treatment plan, has the potential to directly and positively influence the person’s ability to learn and engage with the world around him. This course will introduce practitioners to new advances in our understanding of ASD, including the pivotal role of timing & rhythm for speech, language, pragmatic, cognitive, motor and sensory processing skills. Participants will learn strategies to evaluate the unique strengths and needs of each individual with ASD as well as how to develop and implement effective IM training with consideration for communication, sensory, motor & behavioral challenges. The expert presenter will incorporate several videos and real examples to illustrate techniques. Take the course at https://secure.interactivemetronome.com/NetSite/IM/CEU/SimpleRegistration.aspx?course_id=2778
Slides from Aug 24, 2012 concussion seminar at Saint Brigid of Kildare school, presented by Dr. Mickey Collins and Dr. Jonathan French.
Slides are proprietary material, and are for viewing ONLY. No downloads, embedding or sharing allowed without permission.
The video for this presentation is available on our Youtube channel:
https://youtube.com/allceuseducation A continuing education course for this presentation can be found at https://www.allceus.com/member/cart/index/index?c=
Unlimited Counseling CEUs for $59 https://www.allceus.com/
Specialty Certificate tracks starting at $89 https://www.allceus.com/certificate-tracks/
Live Webinars $5/hour https://www.allceus.com/live-interactive-webinars/
CEs can be earned for this presentation at https://www.allceus.com/member/cart/index/search?q=pharmacology+of+recovery
Pinterest: drsnipes
Nurses, addiction and mental health counselors, social workers and marriage and family therapists can earn CEUs for this and other presentations at AllCEUs.com
Learn how to add certain foods and make little changes to your lifestyle to improve your mood and support recovery from physical illness, mood disorders and addictions.
The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The central nervous system is so named because it integrates information it receives from, and coordinates and influences the activity of, all parts of the bodies
Parkinson's disease is a brain disorder that progressively affects a person’s ability to control body movements, caused by a disorder of certain nerve cells in a part of the brain that produces dopamine, a chemical messenger the brain uses to help direct and control body movement.
Early diagnosis of Parkinson's disease gives you the best chance of a longer, healthier life. This presentation covers the information about biomarkers for Parkinson Diseases which include biological, physiological and imagine candidate / novel biomarkers.
Slides from Aug 24, 2012 concussion seminar at Saint Brigid of Kildare school, presented by Dr. Mickey Collins and Dr. Jonathan French.
Slides are proprietary material, and are for viewing ONLY. No downloads, embedding or sharing allowed without permission.
The video for this presentation is available on our Youtube channel:
https://youtube.com/allceuseducation A continuing education course for this presentation can be found at https://www.allceus.com/member/cart/index/index?c=
Unlimited Counseling CEUs for $59 https://www.allceus.com/
Specialty Certificate tracks starting at $89 https://www.allceus.com/certificate-tracks/
Live Webinars $5/hour https://www.allceus.com/live-interactive-webinars/
CEs can be earned for this presentation at https://www.allceus.com/member/cart/index/search?q=pharmacology+of+recovery
Pinterest: drsnipes
Nurses, addiction and mental health counselors, social workers and marriage and family therapists can earn CEUs for this and other presentations at AllCEUs.com
Learn how to add certain foods and make little changes to your lifestyle to improve your mood and support recovery from physical illness, mood disorders and addictions.
The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The central nervous system is so named because it integrates information it receives from, and coordinates and influences the activity of, all parts of the bodies
Parkinson's disease is a brain disorder that progressively affects a person’s ability to control body movements, caused by a disorder of certain nerve cells in a part of the brain that produces dopamine, a chemical messenger the brain uses to help direct and control body movement.
Early diagnosis of Parkinson's disease gives you the best chance of a longer, healthier life. This presentation covers the information about biomarkers for Parkinson Diseases which include biological, physiological and imagine candidate / novel biomarkers.
JH Alzheimer's and Parkinson's disease meeting presentation Florence March 2013John Harrison
This presentation was made at the AD/PD meeting in Florence on 8th March 2013. In the presentation I discuss early patterns of cognitive dysfunction in patients with Parkinson's disease and Alzheimer's disease. I describe the tests traditionally used to measure cognitive impairment and propose the use of an assessment with the potential to be used successfully in both indications. I propose also that the same collection of measures can profitably be used in other CNS indications. I stress that selection is best made on the basis not of specific tests, but instead on the use of good tests that meet current best practice guidance for measuring cognitive change.
Carrie Bearden: Studying Psychosis in 22q11 Deletion Syndromewef
Presentation made at the live webinar hosted by Schizophrenia Research Forum on the 28th of July, 2016, titled Studying Psychosis in 22q11 Deletion Syndrome. Additional recording and materials available at the SRF website: http://www.schizophreniaforum.org/for/live/detail.asp?liveID=100
The primary onset of this study is to determine the short and longer term effects of dual task training gait on walking performance when dual tasking in people with Parkinson’s disease.. The aim of the study is to analyze the efficacy of dual task training to improve functional gait performance in idiopathic Parkinson’s disease subjects. Design and setting: A randomized controlled study design was used to examine the differences in conventional therapeutic exercises and conventional therapeutic exercises with specific external cueing strategies given between two groups. Subjects: A sample of 10 subjects with idiopathic Parkinson’s disease was screened using Timed up and go test (TUG Test) and those who scored 24% less was taken for the study .the subjects were of both genders aged between 50-75 years of age with medically stable patients. They were divided into two groups of control and experimental group.the study was done in Masterskill College of nursing and health. Outcome Measurement: Functional gait performance will be measured using the timed up and Go (TUG) test with added motor and cognitive tasks, participants will be asked to walk as quickly as they safely can under all conditions and will be permitted to use their usual gait aid. Results: Data Analysis of the subjects after dual task training led to a greater improvement in functional walking capacity and step length. The average percentage of improvement in timed up and go test is 53%. Conclusion: According to this study Dual task training had improved step length and functional walking capacity in idiopathic Parkinson’s disease.
Pat Levitt: Neurodevelopmental Disorder Heterogeneity, Brain Development and ...Beitissie1
In his lecture, Prof. Pat Levitt describes the great heterogeneity of the brain, which makes people different from each other and is a significant challenge to treating people with disabilities.
6. Dietary Compliance and Blood Phe Levels in Patients with PKU Over Time % Patients Above Recommended Blood Phe Level Walter, et al. Lancet . 2002;360:55-7. N = 178 N = 137 N = 98 N = 77
7.
8.
9.
10. Vulnerable Neurocognitive Domains Moyle, et al. Neuropsychol Rev . 2007;17(2):91-101. Motor Skills Information Processing Speed Inhibitory Control Working Memory Attention IQ PKU
11.
12. IQ in Patients with PKU Comparison to Peer Group 1 Comparison to Siblings 2 P < 0.0001 P < 0.001 N = 21 N = 55 N = 55 N = 26 IQ (Wechsler Intelligence Scale) 1) Gassio, et al. Pediatr Neurol . 2005;33(4):267-71. 2) Koch, et al. J Inherit Metab Dis . 1984;7(2):86-90.
13. Impact of Blood Phe Levels on IQ N = 3361 Waisbren, et al. Mol Genet Metabol . 2007;92:63-70. Observation Period Blood Phe Levels ( μ mol/L) Lifetime IQ Loss for Each 100 μ mol/L ↑ in Blood Phe 0 - 12 years old 423 - 750 1.3 - 3.1 points Lifetime 394 - 666 1.9 - 4.1 points
14.
15.
16. Role of Executive Function in Self-Management Executive Task Plan diet Maintain supplies of formula and supplements Record phe intake Resist restricted foods (inhibitory control) Take blood phe levels Adjust diet based on blood phe levels
17.
18.
19. Executive Function in Patients with PKU vs. Control Group Leuzzi, et al. J Inherit Metab Dis . 2004;27(2):115-25. P < 0.001 P < 0.05
20. Working Memory in Patients with PKU vs. Control Group P < 0.05 (all domains) Mean Span White, et al. J Int Neuropsychol Soc . 2002;8:1-11.
21. Inhibitory Control in Patients with PKU vs. Control Group * P < 0.05 vs. control * Number of Errors Christ, et al. Dev Neuropsychol . 2006;30(3):845-64.
22. Strategic Planning in Patients with PKU vs. Normative Data P < 0.05 vs. normative data * * N = 15 VanZutphen, et al. Clin Genet . 2007;72(1):13-8. Test Score
23. Information Processing Speed in Patients with PKU vs. Control Group Anderson, et al. Dev Neuropsychol . 2007;32(2):645-68. Test Score Time to Rapid Retrieval P < 0.01 vs. control (all domains)
24. Memory and Learning Impairments in Patients with PKU White, et al. Neuropsychol . 2001;15(2):221-9. Words Recalled * P < 0.05 vs. control * California Verbal Learning Test Patients up to 11 y.o. Patients ≥ 11 y.o.
25.
26.
27.
28. Academic Difficulties in Patients with PKU vs. Control Group * P < 0.05 vs. control * % Students Gassio, et al. Pediatr Neurol . 2005;33(4):267-71.
29.
30. Neurocognitive Testing * BRIEF-P (preschool version) is available for children aged 2-5 years old. Christ, et al. Mol Genet Metabol . 2010;99(S1):22-32. Janzen, et al. Mol Genet Metabol . 2010;99(S1):47-51. Neurocognitive Domain Test / Assessment Intelligence / IQ Wechsler intelligence scale Executive function • Working memory, attention • Inhibitory control, cognitive flexibility • Planning / organization Behavior rating inventory of executive function (BRIEF*) • Digit span; self-ordered pointing test; trail making test • Stroop color-word test; Wisconsin card sorting test; tower tasks; test of everyday attention for children • Rey-Osterreith complex figure test; tower tasks Non-executive function • Information processing speed • Motor skills • Memory and learning • Symbol digit coding; finger tapping test; trail making test • Purdue test; Peabody developmental motor scales • California verbal learning test; Rey learning tests Academic performance Teacher/parent reports; academic testing Social-emotional adjustment Quality of life questionnaires
31.
32.
33.
34. Psychiatric Symptoms in PKU ↓ Positive Emotions Less joy, happiness, confidence, autonomy, social competence ↑ Negative Emotions More depression, anxiety, phobias, social isolation Brumm, et al. Mol Genet Metabol . 2010;99(S1):59-63. Feillet, et al. Mol Genet Metabol . 2010;99(S1):79-85.
35. Psychiatric Symptoms in PKU Brumm, et al. Mol Genet Metabol . 2010;99(S1):59-63. Untreated Individual Early-Treated Child Early-Treated Adult Aggression Attention problems Decreased positive emotions Anxiety Decreased autonomy Depression Autistic behaviors Decreased social competence Generalized anxiety Depression Less achievement motivation Lack of autonomy Hyperactivity Low self-esteem Low self-esteem Impaired social skills School problems Phobias Psychotic symptoms Social isolation/withdrawal Social withdrawal Social maturity deficits
36. Psychiatric Symptoms in Patients with PKU vs. Control Group Pietz, et al. Pediatrics . 1997;99(3):345-50. Percent of Adult Patients Reporting Symptom P < 0.05 vs. control (all domains) % % % % % % % % % %
37.
38. Stimulant Use for ADHD in Patients with PKU vs. Control Group Control group = patients with diabetes mellitus Arnold, et al. J Inherit Metab Dis . 2004;27(2)137-43. Control Group (N = 76) PKU (N = 38) Percent of patients using stimulants for ADHD ( P < 0.006) ADHD symptoms were associated with higher blood phe levels
39.
40.
41.
42. Assessment by Non-Psychologists Psychological Realm Test / Assessment Adaptive functioning Adaptive behavior assessment system (ABAS-II) Behavior Behavior assessment system for children (BASC-II) Executive function Behavior rating inventory of executive function (BRIEF) (BRIEF-P = preschool version for children aged 2-5 years old)